Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
95 participants
OBSERVATIONAL
2005-01-08
2020-10-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bone Marrow and Blood Samples From Patients With Metastatic Choroid Melanoma
NCT00897624
Study of Tumor Samples in Patients Undergoing Radiation Therapy or Surgery For Primary Melanoma of the Eye
NCT00952939
The Role of Genetic Mutations and of Circulating mRNAs in Uveal Melanoma
NCT05179174
Morphological, Genetic and Tumour Microenvironment Characterisation in Uveal Melanoma
NCT05889481
Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma
NCT00991991
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient with local treatment plan for ocular melanoma- plaque brachytherapy or enucleation
3. Patient 18 years of age or older
4. Archival enucleation specimens with diagnosis of ocular melanoma
Exclusion Criteria
2. Patient who refuses to participate in this study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jonsson Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tara M McCannel, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Jules Stein Eye Institute, UCLA
Bradley R Straatsma, MD, JD
Role: STUDY_DIRECTOR
Jules Stein Eye Institute, UCLA
Lynn Gordon, MD, PhD
Role: STUDY_CHAIR
Jules Stein Eye Institute, UCLA
Ben Glasgow, MD
Role: STUDY_CHAIR
Jules Stein Eye Institute, UCLA
Nagesh P Rao, PhD
Role: STUDY_CHAIR
UCLA Pathology and Laboratory Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jules Stein Eye Institute
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
McCannel TA, Burgess BL, Nelson SF, Eskin A, Straatsma BR. Genomic identification of significant targets in ciliochoroidal melanoma. Invest Ophthalmol Vis Sci. 2011 May 9;52(6):3018-22. doi: 10.1167/iovs.10-5864.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-000847
Identifier Type: OTHER
Identifier Source: secondary_id
UCLA IRB#04-12-084
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.